Yukihiro Umeda
6PUBLICATIONS
2CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Apr 01, 2025
3'-deoxy-3'-18F-fluorothymidine PET imaging of lymphoid tissues in patients with advanced non-small cell lung cancer undergoing anti-programmed cell death-1 therapy.Masayuki Sato, Yukihiro Umeda, Tetsuya Tsujikawa
|Dec 16, 2024
Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report.Yukihiro Umeda, Satomi Kimura, Junya Kimura
|Apr 21, 2023
Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.Tomoaki Sonoda, Yukihiro Umeda, Yoshiki Demura
|Jul 24, 2021
Predictive value of 3'-deoxy-3'-18F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer.Masayuki Sato, Yukihiro Umeda, Tetsuya Tsujikawa
|Apr 30, 2020
Predictive value of integrated 18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer.Yukihiro Umeda, Miwa Morikawa, Masaki Anzai
|Apr 12, 2019
The vertebral 3'-deoxy-3'-18F-fluorothymidine uptake predicts the hematological toxicity after systemic chemotherapy in patients with lung cancer.Yukihiro Umeda, Tetsuya Tsujikawa, Masaki Anzai
Pageof 1
